Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05895747 · ClinicalTrials.gov registry record · Phase 2
5-HTP and Creatine for Depression R33 Phase
A Phase 2 study of Major Depressive Disorder, sponsored by University of Utah.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
- 1
- Study location
NCT05895747: Recruiting Phase 2 study of Major Depressive Disorder, sponsored by University of Utah.
NCT05895747 is a Phase 2 study of Major Depressive Disorder that is actively recruiting participants, run by University of Utah. The registered enrollment target is 106 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05895747, a Phase 2 study of Major Depressive Disorder, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression. Subjects will be randomized between 5-HTP 100mg BID + creatine 5g daily, 5-HTP 200mg BID + creatine 10g daily, vs double placebo, for 8 weeks. The ability of the interventions to affect biomarkers associated with depression will be assessed using brain phosphorus magnetic resonance spectroscopy, functional connectivity imaging, and plasma serotonin levels.
Primary Outcome
Hamilton Depression Rating Scale response: \>=50% reduction in baseline score; maximum possible score is 52, minimum possible score is 0. Higher scores suggest more severe depression.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Low Dose 5-hydroxytryptophan
- DRUG High Dose 5-hydroxytryptophan
- DRUG Low Dose Creatine Monohydrate
- DRUG High Dose Creatine Monohydrate
Study Locations (1)
Utah
- University of Utah Department of Psychiatry - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2023-09-28 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 2 |
What NCT05895747 shows while recruiting
NCT05895747 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT05895747 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT05895747 about?
NCT05895747 is a clinical study titled "5-HTP and Creatine for Depression R33 Phase". This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression. Subjects will be randomized between 5-HTP 100mg BID + creatine 5g daily, 5-HTP 200mg BID + creatine 10g daily, vs double placebo, for 8 week...
What is the current status of trial NCT05895747?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2023-09-28. Estimated completion is 2026-07-31.
What conditions does trial NCT05895747 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT05895747?
The interventions under investigation include: Placebo (DRUG), Low Dose 5-hydroxytryptophan (DRUG), High Dose 5-hydroxytryptophan (DRUG), Low Dose Creatine Monohydrate (DRUG), High Dose Creatine Monohydrate (DRUG).
Who is sponsoring clinical trial NCT05895747?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05895747 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05895747's enrollment target sits among peer trials
106 128th of 282 higher than 155 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI